RU2010100893A - Производные 4-(n-азациклоалкил) анилидов как модуляторы калиевых каналов - Google Patents

Производные 4-(n-азациклоалкил) анилидов как модуляторы калиевых каналов Download PDF

Info

Publication number
RU2010100893A
RU2010100893A RU2010100893/04A RU2010100893A RU2010100893A RU 2010100893 A RU2010100893 A RU 2010100893A RU 2010100893/04 A RU2010100893/04 A RU 2010100893/04A RU 2010100893 A RU2010100893 A RU 2010100893A RU 2010100893 A RU2010100893 A RU 2010100893A
Authority
RU
Russia
Prior art keywords
compound
alkyl
halogen
methyl
independently
Prior art date
Application number
RU2010100893/04A
Other languages
English (en)
Russian (ru)
Inventor
Жан-Мишель ВЕРНЬЕ (US)
Жан-Мишель Вернье
Самеди ОУК (US)
Самеди Оук
ЛА РОСА Марта Алисия ДЕ (US)
ЛА РОСА Марта Алисия ДЕ
Original Assignee
Валеант Фармасьютикалс Интернэшнл (Us)
Валеант Фармасьютикалс Интернэшнл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Валеант Фармасьютикалс Интернэшнл (Us), Валеант Фармасьютикалс Интернэшнл filed Critical Валеант Фармасьютикалс Интернэшнл (Us)
Publication of RU2010100893A publication Critical patent/RU2010100893A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
RU2010100893/04A 2007-06-13 2008-06-13 Производные 4-(n-азациклоалкил) анилидов как модуляторы калиевых каналов RU2010100893A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US93439607P 2007-06-13 2007-06-13
US60/934,396 2007-06-13
US12/138,251 2008-06-12
US12/138,251 US8367684B2 (en) 2007-06-13 2008-06-12 Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators

Publications (1)

Publication Number Publication Date
RU2010100893A true RU2010100893A (ru) 2011-07-20

Family

ID=40137141

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010100893/04A RU2010100893A (ru) 2007-06-13 2008-06-13 Производные 4-(n-азациклоалкил) анилидов как модуляторы калиевых каналов

Country Status (18)

Country Link
US (1) US8367684B2 (enExample)
EP (1) EP2170861B1 (enExample)
JP (1) JP2010530002A (enExample)
KR (1) KR20100018618A (enExample)
CN (1) CN101868451A (enExample)
AU (1) AU2008266009B2 (enExample)
BR (1) BRPI0812564A2 (enExample)
CA (1) CA2689208A1 (enExample)
DK (1) DK2170861T3 (enExample)
ES (1) ES2392774T3 (enExample)
HR (1) HRP20120857T1 (enExample)
MX (1) MX2009013581A (enExample)
PL (1) PL2170861T3 (enExample)
PT (1) PT2170861E (enExample)
RU (1) RU2010100893A (enExample)
SI (1) SI2170861T1 (enExample)
TW (1) TW200914452A (enExample)
WO (1) WO2008157404A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
US20120115900A1 (en) 2009-04-21 2012-05-10 Neurosearch A/S Substituted naphthyridine derivatives and their medical use
US8883812B2 (en) 2010-07-08 2014-11-11 Pfizer Inc. Piperidinyl pyrimidine amides as Kv7 potassium channel openers
MX2014012236A (es) 2012-04-10 2014-11-25 Sumitomo Dainippon Pharma Co Ltd Derivado novedoso de indazol 1-sustituido.
CN103694163A (zh) * 2012-09-27 2014-04-02 上海先声药物研究有限公司 作为钾通道调节剂的化合物
US10702057B2 (en) 2015-07-07 2020-07-07 Colgate-Palmolive Company Oral care implement and monofilament bristle for use with the same
CN110511220B (zh) 2018-05-22 2022-04-01 上海挚盟医药科技有限公司 作为钾通道调节剂的对二氨基苯衍生物、其制备方法及其在医药上的应用
WO2023125935A1 (zh) * 2021-12-31 2023-07-06 上海翰森生物医药科技有限公司 苯并哌啶衍生物调节剂、其制备方法和应用
CN116535353A (zh) * 2022-01-25 2023-08-04 上海挚盟医药科技有限公司 作为钾通道调节剂的酰胺类化合物及其制备和应用

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181803A (en) * 1973-12-14 1980-01-01 Eisai Co., Ltd. Propiophenone derivatives and preparation thereof
DE3369315D1 (en) * 1982-10-27 1987-02-26 Degussa Derivatives of 2-amino-3-acylamino-6-benzylamino pyridine with an anti-epileptic activity
DE3337593A1 (de) 1982-10-27 1984-05-03 Degussa Ag, 6000 Frankfurt 2-amino-3-acylamino-6-benzylamino-pyridin-derivate mit antiepileptischer wirkung
ATE46265T1 (de) * 1985-01-23 1989-09-15 Asta Pharma Ag Synergistische kombination von flupirtin und nicht-steroidalen antiphlogistika.
DE3604575A1 (de) 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
EP0193056B1 (de) * 1985-02-23 1989-06-07 ASTA Pharma Aktiengesellschaft Kombination von Flupirtin und anticholinergisch wirkenden Spasmolytika
JP2583067B2 (ja) * 1987-08-04 1997-02-19 住友化学工業株式会社 モノアゾ化合物およびそれを用いて疎水性繊維材料を染色または捺染する方法
GB8800199D0 (en) * 1988-01-06 1988-02-10 Beecham Group Plc Pharmaceutical preparation
MC2029A1 (fr) * 1988-05-16 1990-04-25 Asta Pharma Ag (n-heterocyclyl)-3 diamino-2,6 pyridines substituees et leurs n-oxydes,preparation de ces composes et leur application comme medicaments
US5629307A (en) * 1989-10-20 1997-05-13 Olney; John W. Use of ibogaine in reducing excitotoxic brain damage
US6004945A (en) * 1990-05-10 1999-12-21 Fukunaga; Atsuo F. Use of adenosine compounds to relieve pain
IN172468B (enExample) * 1990-07-14 1993-08-14 Asta Medica Ag
US5643921A (en) * 1990-09-26 1997-07-01 E.R. Squibb & Sons, Inc. Cardiopulmonary bypass and organ transplant using a potassium channel activator
US5234947A (en) * 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
DE4200259A1 (de) * 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
US5262419A (en) * 1992-06-11 1993-11-16 E. R. Squibb & Sons, Inc. Method for the prophylaxis and/or treatment of ulcerative gastrointestinal conditions using a potassium channel activator
CA2115792C (en) * 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
US5428039A (en) * 1994-02-20 1995-06-27 The Center For Innovative Technology Method for electively achieving reversible hyperpolarized cardiac arrest
US5965582A (en) * 1994-08-03 1999-10-12 Asta Medica Aktiengesellschaft N-benzylindole and benzopyrazole derivatives with anti-asthmatic, anti-allergic, anti-inflammatory and immunemodulating effect
DE69434794T2 (de) * 1994-09-22 2007-07-12 Smith, Richard Alan, La Jolla Kombination von dextromethorphan mit quinidine oder quinine sulfat zur behandlung verschiedener refraktärer störungen
US5679706A (en) * 1994-09-30 1997-10-21 Bristol-Myers Squibb Company Combination of a potassium channel activator and an antiarrhythmic agent
WO1996019233A2 (en) * 1994-12-12 1996-06-27 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm
DE19539861A1 (de) * 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
DE19701694A1 (de) * 1997-01-20 1998-07-23 Asta Medica Ag Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung
IN188411B (enExample) * 1997-03-27 2002-09-21 Yuhan Corp
US5760007A (en) * 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
ATE308342T1 (de) * 1997-08-08 2005-11-15 Chugai Pharmaceutical Co Ltd Arzneimittel gegen diabetes-komplikationen
US6265417B1 (en) * 1997-12-18 2001-07-24 Abbott Laboratories Potassium channel openers
US6593335B1 (en) * 1997-12-18 2003-07-15 Abbott Laboratories Potassium channel openers
US6211171B1 (en) * 1998-05-19 2001-04-03 Dalhousie University Use of antidepressants for local analgesia
JP3441970B2 (ja) 1998-06-30 2003-09-02 株式会社サミー 豆腐の製造方法及び製造装置
JP2000143510A (ja) 1998-11-16 2000-05-23 Taisho Pharmaceut Co Ltd 外用組成物
EP1143956A3 (en) * 1998-12-14 2001-12-12 Cellegy Pharmaceuticals, Inc Compositions and methods for the treatment of anorectal disorders
US6281211B1 (en) * 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
GB9903476D0 (en) * 1999-02-17 1999-04-07 Zeneca Ltd Therapeutic agents
US6451857B1 (en) * 1999-03-10 2002-09-17 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
US6436923B1 (en) 1999-03-17 2002-08-20 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
AT409083B (de) * 1999-04-01 2002-05-27 Sanochemia Pharmazeutika Ag Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung
US6610324B2 (en) 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
GB9915414D0 (en) 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
HK1047036A1 (zh) 1999-07-06 2003-02-07 Eli Lilly And Company 用於治疗偏头痛的选择性iglur5，受体拮抗剂
US6472165B1 (en) 1999-08-03 2002-10-29 Arzneimittelwerk Dresden Gmbh Modulatory binding site in potassium channels for screening and finding new active ingredients
ATE380176T1 (de) * 1999-08-04 2007-12-15 Icagen Inc Benzanilide als öffner des kaliumkanals
EP1200086A4 (en) * 1999-08-04 2009-05-27 Icagen Inc THERAPEUTIC OR PROPHYLACTIC METHODS OF PAIN AND ANXIETY
US6495550B2 (en) * 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
US6117900A (en) * 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
US6383511B1 (en) * 1999-10-25 2002-05-07 Epicept Corporation Local prevention or amelioration of pain from surgically closed wounds
US6538004B2 (en) * 2000-03-03 2003-03-25 Abbott Laboratories Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers
US20020015730A1 (en) * 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
US6348486B1 (en) * 2000-10-17 2002-02-19 American Home Products Corporation Methods for modulating bladder function
US6589986B2 (en) * 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
AU2002256995A1 (en) * 2001-02-07 2002-08-28 Ortho-Mcneil Pharmaceutical, Inc. Pyridoarylphenyl oxazolidinone antibacterials, and related compositions and methods
US6469042B1 (en) * 2001-02-20 2002-10-22 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators if KCNQ potassium channels
AU2002338333A1 (en) 2001-04-04 2002-10-21 Wyeth Methods for treating hyperactive gastric motility
GB0121214D0 (en) 2001-08-31 2001-10-24 Btg Int Ltd Synthetic method
US6831087B2 (en) * 2001-11-09 2004-12-14 Hoffmann-La Roche Inc. Pyridine substituted isoquinoline derivatives
MXPA04007590A (es) * 2002-02-05 2004-12-06 Yamanouchi Pharma Co Ltd Derivado de 2,4,6-triamino-1,3,5-triacina.
AU2003202115A1 (en) 2002-02-12 2003-09-04 Pfizer Inc. Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh)
ATE533743T1 (de) 2002-05-17 2011-12-15 Janssen Pharmaceutica Nv Harnstoffderivate von aminotetralin als modulatoren des vanilloid-rezeptors vr1
WO2003106454A1 (en) 2002-06-12 2003-12-24 Orchid Chemicals & Pharmaceuticals Ltd 1h-isoquinoline-oxazolidinone derivaties and their use as antibacterial agents
AUPS312602A0 (en) * 2002-06-21 2002-07-18 James Cook University Organ arrest, protection, preservation and recovery
US7419981B2 (en) * 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US7045551B2 (en) * 2002-11-22 2006-05-16 Bristol-Myers Squibb Company 1-aryl-2-hydroxyethyl amides as potassium channel openers
ATE488231T1 (de) * 2002-12-23 2010-12-15 Icagen Inc Quinazolinone als kaliumkanalmodulatoren
CA2511502A1 (en) 2002-12-27 2004-07-15 H. Lundbeck A/S 1,2,4-triaminobenzene derivatives,useful for treating disorders of the central nervous system
JP2006520333A (ja) 2003-03-14 2006-09-07 ハー・ルンドベック・アクチエゼルスカベット 置換されたアニリン誘導体
CA2519582A1 (en) 2003-03-21 2004-09-30 H. Lundbeck A/S Substituted p-diaminobenzene derivatives
AU2004233941A1 (en) 2003-04-25 2004-11-11 H. Lundbeck A/S Sustituted indoline and indole derivatives
MXPA05012463A (es) 2003-05-27 2006-01-30 Altana Pharma Ag Combinaciones farmaceuticas de un inhibidor de bomba protonica y un compuesto que modifica la motilidad gastrointestinal.
US7276608B2 (en) * 2003-07-11 2007-10-02 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives as cannabinoid receptor modulators
US20050089473A1 (en) * 2003-09-10 2005-04-28 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier
US7799832B2 (en) * 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
DE10359335A1 (de) 2003-10-23 2005-05-25 Viatris Gmbh & Co. Kg Kombinationen aus Kaliumkanalöffnern und Natriumkanalinhibitoren oder Natriumkanal beeinflussenden Wirkstoffen zur Behandlung von Schmerzzuständen
ES2235626B1 (es) 2003-11-10 2006-11-01 Almirall Prodesfarma, S.A. Formas de administracion masticables, no comprimidas dosificadas individualmente.
TW200530235A (en) * 2003-12-24 2005-09-16 Renovis Inc Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
TWI357901B (en) 2004-03-12 2012-02-11 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivati
JP2007532676A (ja) 2004-04-13 2007-11-15 イカジェン インコーポレイテッド カリウムイオンチャネル調節剤としての多環式ピリジン
CN1968692A (zh) * 2004-05-03 2007-05-23 杜克大学 影响体重减轻的组合物
RU2392278C2 (ru) * 2004-07-15 2010-06-20 Джапан Тобакко Инк. Конденсированное производное бензамида и ингибитор активности подтипа 1 рецептора ваниллоида (vr1)
UA89503C2 (uk) 2004-09-13 2010-02-10 Х. Луннбек А/С Заміщені похідні аніліну
JP2008513508A (ja) * 2004-09-21 2008-05-01 シンタ ファーマシューティカルズ コーポレーション 炎症及び免疫に関連する用途に用いる化合物
EP1813285A4 (en) 2004-11-19 2010-06-09 Kissei Pharmaceutical PROPHYLACTIC OR THERAPEUTIC AGENT AGAINST NEUROPATHIC PAIN
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
WO2006092143A1 (en) 2005-03-03 2006-09-08 H. Lundbeck A/S Substituted pyridine derivatives
US7683058B2 (en) * 2005-09-09 2010-03-23 H. Lundbeck A/S Substituted pyrimidine derivatives
WO2007050348A2 (en) * 2005-10-21 2007-05-03 Merck & Co., Inc. Potassium channel inhibitors
KR20090079191A (ko) 2006-08-23 2009-07-21 밸리언트 파마슈티컬즈 인터내셔널 칼륨 채널 조절제로서 ４-(ｎ-아자사이클로알킬) 아닐리드의 유도체
US8030518B2 (en) 2006-11-28 2011-10-04 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
EP2445340B1 (en) * 2009-06-22 2016-05-18 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof

Also Published As

Publication number Publication date
KR20100018618A (ko) 2010-02-17
TW200914452A (en) 2009-04-01
BRPI0812564A2 (pt) 2015-02-10
AU2008266009A1 (en) 2008-12-24
EP2170861A2 (en) 2010-04-07
AU2008266009B2 (en) 2013-06-06
PL2170861T3 (pl) 2013-01-31
CN101868451A (zh) 2010-10-20
WO2008157404A3 (en) 2009-02-19
DK2170861T3 (da) 2012-11-26
SI2170861T1 (sl) 2012-12-31
EP2170861B1 (en) 2012-08-29
US20080318979A1 (en) 2008-12-25
HRP20120857T1 (hr) 2012-11-30
MX2009013581A (es) 2010-01-26
CA2689208A1 (en) 2008-12-24
JP2010530002A (ja) 2010-09-02
US8367684B2 (en) 2013-02-05
PT2170861E (pt) 2012-09-06
WO2008157404A2 (en) 2008-12-24
ES2392774T3 (es) 2012-12-13

Similar Documents

Publication Publication Date Title
RU2010100893A (ru) Производные 4-(n-азациклоалкил) анилидов как модуляторы калиевых каналов
JP2010530002A5 (enExample)
RU2325381C2 (ru) Замещенные гетероциклические производные и их применение
RU2009149292A (ru) Циклоалкиламины, содержащие в качестве заместителя фенил, как ингибиторы обратного захвата моноаминов
JP2013163667A5 (enExample)
RU2019100164A (ru) Гетероциклическое соединение, используемое как ингибитор fgfr
RU2010154502A (ru) Трициклические 2,4-диамино-l,3,5-триазиновые производные, пригодные для лечения злокачественного новообразования и миелопролиферативных нарушений
RU2016101958A (ru) Пиразольные соединения в качестве модуляторов fshr и их применение
RU2015100901A (ru) Производные эфира гетероарилкарбоновой кислоты
RU2018132037A (ru) Модуляторы эстрогеновых рецепторов
JP2014515349A5 (enExample)
RU2503663C2 (ru) Мостиковые шестичленные циклические соединения
RU2011119990A (ru) Циклоалкиламины в качестве ингибиторов повторного поглощения моноамина
RU2015101106A (ru) Способ лечения лимфомы, применяя тиенотриазолодиазепиновые соединения
RU2005109913A (ru) Азабициклоалкильные эфиры и их применение в качестве агонистов альфа7-nachr
RU2013117464A (ru) Циклопропановые соединения
JP2013542213A5 (enExample)
RU2013118021A (ru) Способы и композиции для лечения сахарного диабета и дислипидемии
RU2016118399A (ru) Производные 4-аминометилбензойной кислоты
RU2013108348A (ru) Конденсированные гетероарилы и их применение
RU2013136895A (ru) Новое бициклическое соединение или его соль
JPWO2021000935A5 (enExample)
IL276711B2 (en) Arginase inhibitors and methods of use thereof
RU2020119562A (ru) Хиназолиноновое соединение и его применение
RU2017131354A (ru) Замещенные амино шестичленные насыщенные гетероалициклы в качестве ингибиторов dpp-iv длительного действия

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20110719